The non-exclusive multi-target license grants TRL rights to use AlivaMab Mouse for antibody drug discovery and development, and to continue and expand the research, development and commercialization of a panel of antibody drug candidates discovered in a pilot project using AlivaMab Mouse at Ablexis' sister company, AlivaMab Discovery Services, LLC.
Financial terms of the license with Ablexis include upfront payments, development milestones and a revenue share on product sales.
Ablexis, LLC created AlivaMab Mouse, a suite of unique, patented next generation transgenic mice, and non-exclusively licenses it as a platform for human therapeutic antibody discovery.
Ablexis has license agreements with dozens of companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making AlivaMab Mouse available via non-exclusive licenses.
AlivaMab Discovery Services is a technology company with an integrated antibody therapeutic discovery platform that combines Ablexis' AlivaMab Mouse platform with innovative technologies and deep expertise to deliver superior antibody therapeutics in rapid timelines.
ADS delivers diverse panels of antibody therapeutic candidates with extensive molecular and epitope diversities, functional and kinetic characterization, and superior developability profiles.
With a business model that focuses exclusively on partners and not developing an internal product pipeline, ADS is trusted by organizations ranging from global pharmaceutical companies to virtual biotechnology organizations.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval